Friday, 23 Aug 2019

You are here

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

There are genetic studies suggesting upregulated calcium-nuclear factor of activated T cells pathway in the pathogenesis of Kawasaki disease.  Moreover there are patients who are predicted to be resistent to IVIG therapy. Thus, this trial set out to assess if targeting these T cells with cyclosporin (CsA) would avert coronary artery abnormalities in Kawasaki patients.

This open-label, multicenter trial from Japan (2014 to 201) enrolled 175 Kawasaki patients predicted to be at higher risk for IVIG resistance and randomized them to receive either IVIG plus CsA (5 mg/kg/D for 5 days) or IVIG. The primary endpoint was incidence of coronary artery abnormalities at  week 12.

Data pm 173 patients showed that coronary artery abnormalities:

  • CsA + IVIG = 14% (Risk ratio 0·46; 95% CI 0·25–0·86; p=0·010)
  • IVIG alone = 31%

Adverse events were not different between the groups (9% vs 7%).

The addition of CsA to IVIG yielded more favourable coronary artery outcomes in Kawasaki disease patients who were predicted to be unresponsive to IVIG.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.